The only commercially available MIGS device currently targeting the supraciliary space now available to patients and surgeons in Sweden and Norway
MINIject is iSTAR Medical’s innovative MIGS device for patients with primary open-angle glaucoma. (Credit: iSTAR Medical)
iSTAR Medical, a medtech company delivering breakthrough eye care solutions to patients, today announced that the commercial rollout expansion for MINIject has continued with the first implantations performed in Sweden and Norway.
MINIject is iSTAR Medical’s minimally-invasive glaucoma surgery (MIGS) implant and is currently the only commercially available supraciliary MIGS device. Patients in Sweden and Norway with open-angle glaucoma are now able to benefit from MINIject, which has demonstrated meaningful and sustained performance in lowering intraocular pressure (IOP), combined with a favorable safety profile.
Patients were successfully implanted with MINIject at Ögonmottagningen, Östersunds sjukhus, Östersund, Sweden by Dr Anna Barkander and in the South East region of Norway. This follows iSTAR Medical’s recent expansion of MINIject into Switzerland in May and expands iSTAR Medical’s portfolio of European territories where MINIject is now available for patients, alongside Germany and the UK.
Dr Anna Barkander, Head of the Department of Ophthalmology at Östersunds sjukhus (Sweden), commented: “MIGS plays an important role in the treatment of glaucoma, providing us with more opportunities to treat the heterogenous group of glaucoma patients. I’m pleased that I can now provide my open-angle glaucoma patients access to MINIject, since the supraciliary space is an effective target to lower IOP and thus help delay disease progression and preserve patient vision.”
Michel Vanbrabant, CEO of iSTAR Medical, commented: “We continue to progress in our mission to preserve the vision of glaucoma patients globally with our expansion across Europe. Approximately 100,000 individuals are diagnosed with glaucoma in Sweden every year, with many more undiagnosed.[1] In neighboring Norway, approximately 77,000 individuals are treated for glaucoma each year, representing 1% of its population, but 8% of the population aged over 70 years old.[2] We are excited to be able to provide patients and surgeons in Sweden and Norway access to MINIject, which is currently the only commercially available MIGS device targeting the power of the supraciliary space to lower IOP.”
Source: Company Press Release